Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukine + Paclitaxel in Advanced Melanoma
NCT00278122Phase 2Suspended
- Sponsor
- University of Virginia
- Start
- Jul 2005
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in melanoma, sponsored by University of Virginia. Primary endpoint: Objective Clinical Response Rate. Started Jul 2005; status: suspended.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00278122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278122.